Journal article
Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial.
- Gobbi C Neurocentre of Southern Switzerland, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano, Lugano, Switzerland. claudio.gobbi@eoc.ch
- Digesu GA
- Khullar V
- El Neil S
- Caccia G
- Zecca C
- 2011-07-16
Published in:
- Multiple sclerosis (Houndmills, Basingstoke, England). - 2011
Adult
Electric Stimulation Therapy
Female
Humans
Lower Urinary Tract Symptoms
Male
Middle Aged
Multiple Sclerosis
Prospective Studies
Quality of Life
Surveys and Questionnaires
Tibial Nerve
Treatment Outcome
Urinary Incontinence
English
BACKGROUND
Percutaneous tibial nerve stimulation (PTNS) has been proposed as a new, minimally invasive neuromodulation technique to treat lower urinary tract symptoms (LUTS).
OBJECTIVE
To evaluate efficacy, safety and impact on quality of life (QoL) of PTNS on patients with multiple sclerosis (MS) who have LUTS.
METHODS
21 patients (5 men, 16 women) with MS and LUTS unresponsive to anticholinergics were treated with 12 sessions of PTNS. Assessment of LUTS was by validated, self-administered chart and questionnaires, testing the subjective and objective relevance of LUTS for patients and their impact on QoL before and after treatment; the mean post-micturition residual was assessed by trans-abdominal ultrasound scanning. Analysis was by intention to treat.
RESULTS
There was a significant reduction of daytime frequency (from 9 to 6, p = 0.04), nocturia (from 3 to 1, p = 0.002) and mean post-micturition residual (from 98 ± 124 ml to 43 ± 45 ml, p = 0.02). The mean voided volume increased from 182 ± 50 ml to 225 ± 50 ml (p = 0.003). Eighty-nine percent of patients reported a treatment satisfaction of 70%. Significant improvement in QoL was seen in most domains of the King's Health QoL questionnaire (p < 0.05). No adverse events were reported.
CONCLUSIONS
PTNS is an effective, safe and well-tolerated treatment for LUTS in patients with MS.
Percutaneous tibial nerve stimulation (PTNS) has been proposed as a new, minimally invasive neuromodulation technique to treat lower urinary tract symptoms (LUTS).
OBJECTIVE
To evaluate efficacy, safety and impact on quality of life (QoL) of PTNS on patients with multiple sclerosis (MS) who have LUTS.
METHODS
21 patients (5 men, 16 women) with MS and LUTS unresponsive to anticholinergics were treated with 12 sessions of PTNS. Assessment of LUTS was by validated, self-administered chart and questionnaires, testing the subjective and objective relevance of LUTS for patients and their impact on QoL before and after treatment; the mean post-micturition residual was assessed by trans-abdominal ultrasound scanning. Analysis was by intention to treat.
RESULTS
There was a significant reduction of daytime frequency (from 9 to 6, p = 0.04), nocturia (from 3 to 1, p = 0.002) and mean post-micturition residual (from 98 ± 124 ml to 43 ± 45 ml, p = 0.02). The mean voided volume increased from 182 ± 50 ml to 225 ± 50 ml (p = 0.003). Eighty-nine percent of patients reported a treatment satisfaction of 70%. Significant improvement in QoL was seen in most domains of the King's Health QoL questionnaire (p < 0.05). No adverse events were reported.
CONCLUSIONS
PTNS is an effective, safe and well-tolerated treatment for LUTS in patients with MS.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1177/1352458511414040
- PMID 21757534
- Persistent URL
- https://sonar.ch/global/documents/70542
Statistics
Document views: 13
File downloads: